CompletedPhase 3NCT03636269
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frédérique Menzaghi, PhD, DDSCara Therapeutics
- Intervention
- CR845 0.5 mcg/kg(drug)
- Enrollment
- 473 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (30)
- Cara Therapeutics Study Site, Chula Vista, California, United States
- Cara Therapeutics Study Site, Fountain Valley, California, United States
- Cara Therapeutics Study Site, Northridge, California, United States
- Cara Therapeutics Study Site, Riverside, California, United States
- Cara Therapeutics Study Site 2, San Dimas, California, United States
- Cara Therapeutics Study Site, San Dimas, California, United States
- Cara Therapeutics Study Site, Westminster, Colorado, United States
- Cara Therapeutics Study Site, Hialeah, Florida, United States
- Cara Therapeutics Study Site, Miami Gardens, Florida, United States
- Cara Therapeutics Study Site, Orlando, Florida, United States
- Cara Therapeutics Study Site, Athens, Georgia, United States
- Cara Therapeutics Study Site, Macon, Georgia, United States
- Cara Therapeutics Study Site, Baton Rouge, Louisiana, United States
- Cara Therapeutics Study Site, Brockton, Massachusetts, United States
- Cara Therapeutics Study Site, Kalamazoo, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03636269 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.